APNmAb005 / APRINOIA Therap - LARVOL DELTA

High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005). (PubMed, FASEB J) - "By contrast, total Tau and p181 Tau showed 1/4-1/5 levels of AD even at Stage I, while both tau species also showed a statistically significant increase in AD. In sum, our novel APNmAb005-ELISA clarified the disease-specific increase in HMWoTau species and will be useful for not only further etiological elucidation but also the potential diagnostics in AD and relevant tauopathy."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders

Passive tau-based immunotherapy for tauopathies. (PubMed, Handb Clin Neurol) - "At present, 12 anti-tau antibodies have entered clinical trials, and 7 of them are still in clinical testing for primary tauopathies and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, PNT00, and APNmAb005). Two other anti-tau monoclonal antibodies have been discontinued for the treatment of primary tauopathies, i.e., gosuranemab and tilavonemab. Further evidence will come from ongoing Phase I/II trials on passive immunotherapeutics for treating primary and secondary tauopathies."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy

APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies (AAIC 2023) - "APNmAb005 is a conformation selective antibody that binds to tau oligomers and aggregates preferentiually in synapses in pathological brain tissues and inhibits tau spreading. The mid-region conformation dependent epitope is distinct from all other tau antibodies currently in clinical development. APNmAb005 offers a unique tau immunotherapy for neurodegenerative disorders and is currently in Phase 1 to evaluate its safety and tolerability."

P1 data • Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • Solid Tumor

Clinical Development of Passive Tau-Based Immunotherapeutics for Treating Primary and Secondary Tauopathies. (PubMed, Expert Opin Investig Drugs) - "At present, 14 anti-tau antibodies have entered clinical trials, and 9 of them are still in clinical testing for progressive supranuclear palsy syndrome and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, APNmAb005, MK-2214, PNT00, and PRX005). The most advanced anti-tau monoclonal antibody for treating AD is semorinemab, while bepranemab is the only anti-tau monoclonal antibody still in clinical testing for treating progressive supranuclear palsy syndrome. Further evidence on passive immunotherapeutics for treating primary and secondary tauopathies will come from ongoing Phase I/II trials."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: APRINOIA Therapeutics, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ Jul 2024 | Trial primary completion date: Jan 2023 ➔ Mar 2024

Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Plasma T-Tau

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: APRINOIA Therapeutics, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Plasma T-Tau

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: APRINOIA Therapeutics, LLC

New P1 trial • Alzheimer's Disease • CNS Disorders • Plasma T-Tau

[VIRTUAL] SYNAPTICALLY PREFERRED ANTI-TAU ANTIBODIES REDUCE IN VITRO TAU SEEDING AND IN VIVO NEURONAL LOSS (AAIC 2020) - "The therapeutic potentials of anti-tau antibodies are not judged by the location of epitopes or sub-cellular localization, but by their abilities to recognize synaptically localized tau in AD brains."

Preclinical • Alzheimer's Disease • CNS Disorders

[VIRTUAL] SYNAPTICALLY PREFERRED ANTI-TAU ANTIBODIES REDUCE IN VITRO TAU SEEDING AND IN VIVO NEURONAL LOSS (AAIC 2020) - "The therapeutic potentials of anti-tau antibodies are not judged by the location of epitopes or sub-cellular localization, but by their abilities to recognize synaptically localized tau in AD brains."

Preclinical • Alzheimer's Disease • CNS Disorders